CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for RVL Pharmaceuticals PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

RVL Pharmaceuticals PLC
400 CROSSING BOULEVARD
Phone: (908) 809-1300p:908 809-1300 BRIDGEWATER, NJ  08807  United States Ticker: RVLPQRVLPQ
Business Summary
RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Chief Financial Officer Brian A.Markison 63 4/15/2022 1/1/2016
Chief Operating Officer, Executive Vice President JamesSchaub 41 1/1/2016 1/1/2016
General Counsel, Secretary ChristopherKlein 59 12/1/2013 12/1/2013
3 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
RevitaLid Pharmaceutical Corp. 400 Crossing Boulevard Bridgewater NJ United States

Business Names
Business Name
Osmotica Argentina, S.A.
Osmotica Kereskedelmi es Szolgaltato Kft
Osmotica Pharmaceutical Corp.
7 additional Business Names available in full report.

General Information
Number of Employees: 125 (As of 12/31/2022)
Outstanding Shares: 111,406,043 (As of 8/30/2023)
Shareholders: 3
Stock Exchange: OTC


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024